WALTHAM, Mass., Dec. 20, 2017 /PRNewswire/ -- Juno Therapeutics
(NASDAQ: JUNO) and Thermo Fisher Scientific have entered into a
partnership for Juno to use Thermo
Fisher's Cell Therapy Systems (CTS) activation reagents in
the manufacturing of its chimeric antigen receptor T cell (CAR T)
therapies.
Under the seven-year nonexclusive licensing and supply
agreement, Juno has obtained rights to use CTS Dynabeads CD3/CD28
magnetic beads as part of the clinical and commercial manufacturing
processes for its current and future CAR T therapies. CTS Dynabeads
activate and expand T cells that have been genetically engineered
to recognize and fight cancer cells in each individual patient. The
proprietary platform already enables research, development, and
commercialization of other CAR T cell therapies globally by
providing a scalable platform that streamlines production while
ensuring high reproducibility.
"Juno aims to manufacture best-in-class CAR T therapies to help
as many patients as we can," said Ann L.
Lee, Juno's Executive Vice President of Technical
Operations. "Thermo Fisher's
technology will help us do that and deliver on our promise to
patients."
"As Juno progresses its pipeline from clinical research to
commercializing drug product, it requires the highest-quality
manufacturing capabilities that the industry can offer," said
Mark Stevenson, Chief Operating
Officer, Thermo Fisher Scientific. "Cell Therapy Systems' products
help minimize the risk of contamination and variability in clinical
research and drug commercialization. These products are supported
by rigorous regulatory review, making them a proven choice as more
companies invest in moving from bench to bedside."
No other terms from this transaction were disclosed.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving
science, with revenues of more than $20
billion and approximately 65,000 employees globally. Our
mission is to enable our customers to make the world healthier,
cleaner and safer. We help our customers accelerate life sciences
research, solve complex analytical challenges, improve patient
diagnostics, deliver medicines to market and increase laboratory
productivity. Through our premier brands – Thermo Scientific,
Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab
Services – we offer an unmatched combination of innovative
technologies, purchasing convenience and comprehensive services.
For more information, please visit www.thermofisher.com.
About Juno
Juno Therapeutics is building a fully integrated
biopharmaceutical company focused on developing innovative cellular
immunotherapies for the treatment of cancer. Founded on the vision
that the use of human cells as therapeutic entities will drive one
of the next important phases in medicine, Juno is developing
cell-based cancer immunotherapies based on chimeric antigen
receptor and high-affinity T cell receptor technologies to
genetically engineer T cells to recognize and kill cancer. Juno is
developing multiple cell-based product candidates to treat a
variety of B-cell malignancies as well as multiple solid tumors and
multiple myeloma. Several product candidates have shown compelling
clinical responses in clinical trials in refractory leukemia and
lymphoma conducted to date. Juno's long-term aim is to leverage its
cell-based platform to develop new product candidates that address
a broader range of cancers and human diseases. Juno brings together
innovative technologies from some of the world's leading research
institutions, including the Fred Hutchinson Cancer Research Center,
Memorial Sloan Kettering Cancer Center, Seattle Children's Research
Institute (SCRI), the University of
California, San Francisco, and The National Cancer
Institute. Juno Therapeutics has an exclusive license to the St.
Jude Children's Research Hospital patented technology for
CD19-directed product candidates that use 4-1BB, which was
developed by Dario Campana,
Chihaya Imai, and St. Jude
Children's Research Hospital. Juno's product candidate JCAR017 was
developed in collaboration with SCRI and others.
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," "outlook" and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. Celgene and Juno undertake no obligation to update
any forward-looking statement in light of new information or future
events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which
are difficult to predict and are generally beyond the control of
either company. Actual results or outcomes may differ materially
from those implied by the forward-looking statements as a result of
the impact of a number of factors, many of which are discussed in
more detail in the public reports of each company filed with
the Securities and Exchange Commission.
Media Contact Information
Ron O'Brien
Thermo Fisher Scientific
781-622-1242
ron.obrien@thermofisher.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/juno-therapeutics-and-thermo-fisher-scientific-announce-car-t-manufacturing-partnership-300573836.html
SOURCE Thermo Fisher Scientific
